Navigation Links
Mosquito genes linked to insecticide resistance may be new target in fight against malaria
Date:2/4/2009

Malaria remains one of the most serious diseases worldwide, claiming the lives of more than one million people per year in tropical and sub-tropical regions, the majority of whom are children under five years of age. Efforts to eliminate this mosquito-borne illness rely heavily on prevention measures, but there are growing concerns about resistance to insecticides. In a study published online today in Genome Research (www.genome.org), researchers have identified specific mosquito genes associated with resistance to a common class of insecticide, a significant step toward the execution of more effective malaria control strategies.

Eradication of mosquitoes that carry the malarial parasite has relied heavily on the use of insecticides for spraying inside of homes and treatment of mosquito netting. There are very few insecticides that are both effective and low-cost, while at the same time safe for humans. Developing new insecticides will be time consuming and expensive, therefore understanding the genetic and biological basis of resistance to insecticides currently in use will be critical for more effective prevention measures in the field.

In this study, an international team of scientists led by Dr. Charles Wondji of the Liverpool School of Tropical Medical has identified the genetic basis of resistance to common pyrethroid insecticides in the mosquito Anopheles funestus, one of the major malarial vectors in Africa. The group studied strains of An. funestus that are both susceptible and resistant to pyrethroids, and narrowed down the potential genetic culprits to members of a family of genes coding for enzymes known as cytochrome P450s. The P450s are common to all classes of organisms, and are considered a first line of defense against toxins.

The researchers found two cytochrome P450 genes in An. funestus that are associated with pyrethroid resistance. Dr. Hilary Ranson of the Liverpool School of Tropical Medicine, a co-author of the study, explained that what makes this finding remarkable is that this particular type of cytochrome P450s were also recently implicated in pyrethroid resistance in Anopheles gambiae, the other major malaria-carrying mosquito in Africa. "If the enzymes responsible for resistance are very similar in both species, there is a much greater incentive to invest efforts in identifying specific enzyme inhibitors with the knowledge that they will likely be effective at overcoming resistance in both major malaria vectors," said Ranson. Furthermore, Ranson noted it is critical that these mosquito P450 genes do not have close relatives in the human genome, meaning that targets developed against these mosquitoes should have low risk for toxicity in humans.

This report of genetic markers that can be used to predict insecticide resistance in laboratory populations of An. funestus may be a landmark finding in malaria prevention when applied to the evaluation of wild mosquito populations. "Routine use of these molecular markers for resistance will provide early warning of future control problems due to insecticide resistance and should greatly enhance our ability to mitigate the potentially devastating effects of resistance on malaria control," said Ranson.


'/>"/>

Contact: Peggy Calicchia
calicchi@cshl.edu
516-422-4012
Cold Spring Harbor Laboratory
Source:Eurekalert

Related biology technology :

1. Virginia Tech researchers discover how mosquitoes avoid succumbing to viruses they transmit
2. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
3. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
4. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
5. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
6. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
7. Cell Genesys to Present at the BIO Investor Forum
8. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
9. Massive reanalysis of genome data solves case of the lethal genes
10. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
11. Cell Genesys to Webcast Third Quarter 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have recently emerged ... of the Protein and Cell Analysis Education Webinar Series , will focus on ... in current and future applications. , Many flow cytometers have unique capabilities and ...
(Date:4/19/2017)... Waltham, MA (PRWEB) , ... April 19, 2017 ... ... of a $1.5M Series A-1 financing round. This event adds to several other ... establishment of its’ Executive and Scientific Teams. , ThermaGenix will use ...
(Date:4/19/2017)... 2017  As a Bronze Sponsor of ... ,  Proove® Biosciences, Inc. announces the first-ever ... lifestyle factors to accurately predict prescription opioid abuse. In ... California (USC), the Interventional Pain Institute in ... showing that Proove Opioid Risk® accurately identifies patients ...
(Date:4/18/2017)... ... April 18, 2017 , ... METTLER TOLEDO Process ... concentration levels and vice-versa. , One of the key applications for the measurement ... control or monitoring. The principle of this analytical method is based on pure ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):